Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.60 |
| ▸ | GSK3A | P49840 | 4/20 | 0.60 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161701 | 0.91 | GSK3B (0.59) | GSK3BGSK3AMAPT | |
| SCHEMBL4147509 | 0.91 | GSK3B (0.59) | GSK3BGSK3AMAPT | |
| SCHEMBL4152202 | 0.90 | GSK3B (0.56) | GSK3BGSK3APKN1PKN2 | |
| SCHEMBL13778056 | 0.90 | GSK3B (0.52) | GSK3BGSK3AMAPT | |
| SCHEMBL8237753 | 0.90 | GSK3B (0.61) | GSK3BGSK3AMAPT | |
| SCHEMBL4169267 | 0.90 | GSK3B (0.76) | GSK3BGSK3A | |
| SCHEMBL4153410 | 0.86 | GSK3B (0.59) | GSK3BGSK3AMAPTALDH1A1GAA | |
| SCHEMBL4157388 | 0.86 | GSK3B (0.59) | GSK3BGSK3AMGAMGAASI | |
| SCHEMBL4152722 | 0.86 | GSK3B (0.60) | GSK3BGSK3AMGAMGAASI | |
| SCHEMBL4149980 | 0.85 | GSK3B (0.58) | GSK3BGSK3AMAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | claimed |
| EP-1984370-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Crystalgenomics, Inc. (KR) | 2008-10-29 | — | — | EP | claimed |
| WO-2007083978-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-07-26 | — | — | WO | claimed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | GSK3B, GSK3A, MAP3K3 | GSK3B 1/4885GSK3A 2/4885PKN1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.